Peregrine's Combination Therapy Reduces Tumor Growth By 95%
Posted on: Thursday, 17 April 2008, 03:00 CDT
Peregrine Pharmaceuticals has reported that a mouse equivalent of the company's anti-phosphatidylserine vascular targeting antibody bavituximab administered in combination with the chemotherapeutic agent docetaxel demonstrated excellent signs of efficacy in a preclinical model of hormone-refractory prostate cancer.
The study showed that in a mouse model of hormone-refractory prostate cancer, the combination of the bavituximab equivalent antibody 2aG4 and the chemotherapy drug docetaxel significantly decreased the growth of tumors, eliminated detectable metastases and prevented tumor re-growth. This increase in anti-tumor efficacy and anti-metastatic activity was achieved with no apparent increase in toxicity compared to docetaxel alone.
Specifically, in the study 2aG4 administered with docetaxel reduced primary tumor burden by 95%, an anti-tumor effect that was significantly superior to that of the individual treatments administered alone. Treatment with the combination of 2aG4 and docetaxel also reduced the metastatic spread of tumor cells. In animals treated with the combination regimen, none of the treated mice exhibited detectable metastatic lesions, while 100% of the mice treated with a non-specific control antibody, 67% of mice treated with 2aG4 alone and half the mice treated with docetaxel alone exhibited metastatic lesions.
The combination was also superior at preventing tumor re-growth. Survival time was more than doubled in animals receiving combination therapy compared to controls, and was substantially longer than the survival of animals treated with either therapy alone.
Steven King, president and CEO of Peregrine, said: "We are currently testing the combination regimen of bavituximab and docetaxel in a Phase II trial in patients with breast cancer, and we look forward to potentially assessing bavituximab in combination regimens in prostate cancer in future clinical trials."
Source: Datamonitor
Related Articles
- Considering Combination Versus Sequential Chemotherapy In Metastatic Breast Cancer
- Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen
- Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
- New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer and Other Difficult-to-Treat Tumor Types to Be Presented at ASCO
- Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
- Immunicon Corporation Announced the Filing for FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients With Metastatic Androgen-Independent Prostate Cancer
- Unique Structure of Geron's Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells
- Immunicon Achieves Endpoint in Its Pivotal Clinical Trial in Metastatic Androgen-Independent Prostate Cancer
- Avantogen Oncology Inc. Announces Preliminary Results of a Dose Ranging Study of RP101 in Combination With Gemcitabine Chemotherapy in Patients With Advanced Pancreatic Cancer
- FDA Agrees to File Abbott's New Drug Application for Xinlay(TM) (Atrasentan) to Treat Metastatic Hormone-Refractory Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds